Sugi Predict
/ Targets
/ MYC
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to MYC by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas |
PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING |
| Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors |
PHASE1/PHASE2 | COMPLETED |
| DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer |
PHASE1/PHASE2 | RECRUITING |
| Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma |
PHASE2 | ACTIVE_NOT_RECRUITING |
| A Study to Evaluate Efficacy & Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Richter's Syndrome; |
PHASE2 | COMPLETED |
| Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer |
PHASE1/PHASE2 | COMPLETED |
| EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma |
PHASE2 | COMPLETED |
| BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors |
PHASE2 | WITHDRAWN |
| Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers |
PHASE1/PHASE2 | COMPLETED |
| Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma |
PHASE2 | COMPLETED |
| A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders |
PHASE1/PHASE2 | COMPLETED |
| Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients |
PHASE2 | COMPLETED |
| Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma |
PHASE2 | RECRUITING |
| Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA |
PHASE1 | RECRUITING |
| Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas |
PHASE1 | COMPLETED |
| Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer |
PHASE1 | ACTIVE_NOT_RECRUITING |
| CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies |
PHASE1 | RECRUITING |
| Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma |
EARLY_PHASE1 | RECRUITING |
| Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831 |
nan | COMPLETED |
| Differential Expression and Potential Value of c-MYC in Non-Invasive and Invasive Mammary Carcinoma |
nan | UNKNOWN |
| Development of IPS from Donated Somatic Cells of Patients with Neurological Diseases |
nan | RECRUITING |
| A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma |
nan | RECRUITING |
| Cell Membrane Potential Regulates Spatial-Specific Mechanoptosis Resistance and Metastasis in Colorectal Cancer Via Mechanotransduction and the PVR/CD96 Axis |
nan | COMPLETED |
| Next Generation Pre-clinical Model for Colorectal Cancer Metastases and Hepatocellular Carcinomas |
nan | COMPLETED |
| Role of RPL8 Protein Alterations in High-grade Serous Ovarian Carcinoma |
nan | RECRUITING |
| Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma |
nan | RECRUITING |
| Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a MYC binder may also engage these)